GUANGZHOU, China – China's health care reforms have made great strides toward developing the country's pharmaceutical industry, but the current ecosystem may not be enough for China to compete on the world stage of drug development, said industry experts and regulators at this week's GF Securities Life Sciences Investment Conference.